Malaria remains a significant contributor to the global burden of disease, with around 40% of
the world's population at risk of Plasmodium infections. The development of an effective …

Developing efficacious vaccines for human malaria caused by Plasmodium falciparum is a
major global health priority, although this has proven to be immensely challenging over the …

Numerous efforts to understand the functional roles of antibodies demonstrated that they can
protect against malaria. However, it is unclear which antibody responses are the best …

Malaria is a major cause of disease and death in tropical countries. A safe and effective
vaccine is essential to achieve significant and sustained reductions in malaria-related …

Most studies on human immunity to malaria have focused on the roles of immunoglobulin G
(IgG), whereas the roles of IgM remain undefined. Analyzing multiple human cohorts to …

The blood stage of the malaria parasite's life cycle is responsible for all the clinical
symptoms of malaria. The development of clinical disease is dependent on the interplay of …

Malaria is possibly the most serious infectious disease of humans, infecting 5–10% of the
world's population, with 300–600 million clinical cases and more than 2 million deaths …

Malaria is a global infectious disease that remains a leading cause of morbidity and mortality
in the developing world. Multiple environmental and host and parasite factors govern the …

Evidence accumulated through the years clearly indicates that antiparasite immune
responses can efficiently control malaria parasite infection at all development stages, and …

Malaria is a mosquito-borne disease caused by parasites of the obligate intracellular
Apicomplexa phylum the most deadly of which, Plasmodium falciparum, prevails in Africa …